JP5739344B2 - Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法 - Google Patents

Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法 Download PDF

Info

Publication number
JP5739344B2
JP5739344B2 JP2011534860A JP2011534860A JP5739344B2 JP 5739344 B2 JP5739344 B2 JP 5739344B2 JP 2011534860 A JP2011534860 A JP 2011534860A JP 2011534860 A JP2011534860 A JP 2011534860A JP 5739344 B2 JP5739344 B2 JP 5739344B2
Authority
JP
Japan
Prior art keywords
thc
amino acid
derivative
composition
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011534860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507568A (ja
JP2012507568A5 (enExample
Inventor
マフムード エイ エルソーリー
マフムード エイ エルソーリー
ワシーム グル
ワシーム グル
マイケル エイ レプカ
マイケル エイ レプカ
ソウムヤジット マジュムダル
ソウムヤジット マジュムダル
Original Assignee
ザ ユニヴァーシティー オブ ミシシッピ
ザ ユニヴァーシティー オブ ミシシッピ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニヴァーシティー オブ ミシシッピ, ザ ユニヴァーシティー オブ ミシシッピ filed Critical ザ ユニヴァーシティー オブ ミシシッピ
Publication of JP2012507568A publication Critical patent/JP2012507568A/ja
Publication of JP2012507568A5 publication Critical patent/JP2012507568A5/ja
Application granted granted Critical
Publication of JP5739344B2 publication Critical patent/JP5739344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B13/00—Accessories or details of general applicability for machines or apparatus for cleaning
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B3/00—Cleaning by methods involving the use or presence of liquid or steam
    • B08B3/02—Cleaning by the force of jets or sprays
    • B08B3/026—Cleaning by making use of hand-held spray guns; Fluid preparations therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B2203/00—Details of cleaning machines or methods involving the use or presence of liquid or steam
    • B08B2203/02—Details of machines or methods for cleaning by the force of jets or sprays
    • B08B2203/0264—Splash guards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
JP2011534860A 2008-10-31 2009-11-02 Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法 Active JP5739344B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11016508P 2008-10-31 2008-10-31
US61/110,165 2008-10-31
PCT/US2009/062998 WO2010051541A2 (en) 2008-10-31 2009-11-02 Compositions containing delta-9-thc-amino acid esters and process of preparation

Publications (3)

Publication Number Publication Date
JP2012507568A JP2012507568A (ja) 2012-03-29
JP2012507568A5 JP2012507568A5 (enExample) 2012-12-20
JP5739344B2 true JP5739344B2 (ja) 2015-06-24

Family

ID=42129588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534860A Active JP5739344B2 (ja) 2008-10-31 2009-11-02 Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法

Country Status (10)

Country Link
US (2) US8809261B2 (enExample)
EP (1) EP2352497B1 (enExample)
JP (1) JP5739344B2 (enExample)
AU (1) AU2009308665B2 (enExample)
CA (1) CA2741862C (enExample)
DK (1) DK2352497T3 (enExample)
ES (1) ES2622582T3 (enExample)
HU (1) HUE032158T2 (enExample)
PL (1) PL2352497T3 (enExample)
WO (1) WO2010051541A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US8991402B2 (en) 2007-12-18 2015-03-31 Pax Labs, Inc. Aerosol devices and methods for inhaling a substance and uses thereof
HUE032158T2 (en) * 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
US10517530B2 (en) 2012-08-28 2019-12-31 Juul Labs, Inc. Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances
DK2895144T3 (en) 2012-09-12 2017-03-06 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS
EP3100722B1 (en) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
AU2014262808B2 (en) 2013-05-06 2018-12-13 Juul Labs, Inc. Nicotine salt formulations for aerosol devices and methods thereof
CN111642812A (zh) 2013-06-14 2020-09-11 尤尔实验室有限公司 电子汽化设备中的具有单独的可汽化材料的多个加热元件
KR20240070710A (ko) 2013-12-05 2024-05-21 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 액제 및 그 방법
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
PT3504991T (pt) 2013-12-23 2021-03-01 Juul Labs Int Inc Sistemas de dispositivo e métodos de vaporização
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US11478021B2 (en) 2014-05-16 2022-10-25 Juul Labs, Inc. Systems and methods for aerosolizing a vaporizable material
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2969728C (en) 2014-12-05 2023-06-13 Pax Labs, Inc. Calibrated dose control
AU2016231788A1 (en) * 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CN105037180B (zh) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
WO2016186735A1 (en) 2015-05-18 2016-11-24 5071, Inc. Homogenous cannabis compositions and methods of making the same
EP3297617A4 (en) * 2015-05-18 2019-02-20 5071, Inc. HOMOGENEOUS CANNABIC COMPOSITION AND METHOD FOR THE MANUFACTURE THEREOF
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3407973B1 (en) * 2016-01-29 2023-07-26 The University Of Mississippi Biologically active cannabidiol analogs
MX377347B (es) 2016-02-11 2025-03-07 Juul Labs Inc Cartucho rellenable de vaporizador y metodo de relleno
CO2018009342A2 (es) 2016-02-11 2018-09-20 Juul Labs Inc Cartuchos de fijación segura para dispositivos vaporizadores
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
EP3442522A4 (en) 2016-04-15 2020-01-01 SRE Wellness, Inc. METHOD FOR PRODUCING HYDROPHILIZED CANNABI OIL USING EMULSIFIERS AND RELATED CANNABINOID COMPOSITIONS
CA3021093A1 (en) 2016-04-15 2017-10-19 Sre Wellness, Inc. Cannabis infused sweeteners and other compositions
AU2017286335A1 (en) * 2016-06-16 2019-01-17 Teewinot Technologies Limited Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
US11660403B2 (en) 2016-09-22 2023-05-30 Juul Labs, Inc. Leak-resistant vaporizer device
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
US20190343793A1 (en) 2016-09-28 2019-11-14 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
MX2019011980A (es) * 2017-04-05 2020-07-29 Univ Mississippi Aislamiento de cannabinoides puros a partir de cannabis.
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
EP3424493A1 (en) 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
US20190015383A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
EP3672587A4 (en) * 2017-08-27 2021-05-19 Rhodes Technologies PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11498018B2 (en) * 2017-11-27 2022-11-15 Vasilios (Bill) Panagiotakopoulos Extraction and purification of cannabinoid compounds
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3876907A4 (en) * 2018-11-07 2022-08-10 Columbia Care LLC CANNABINOID SUPPOSITORY FORMULATIONS
EP3923915A4 (en) * 2019-02-11 2023-03-22 John Robert Chancey METHODS OF PREPARATION AND USE OF PHYTOCANNABINOIDS IN A COMPLEX WITH A PROTEIN, PEPTIDE, AMINO ACID, POLYSACCHARIDE, DISACCHARIDE OR MONOSACCHARIDE
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
US20220177666A1 (en) * 2019-03-12 2022-06-09 6th Wave Innovations Corp. Molecularly imprinted polymers for extraction of cannabinoids and uses thereof
US20220168238A1 (en) * 2019-04-09 2022-06-02 Village Flora, Inc. Methods and compositions for use in treatment of cancer without psychoactive effects
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
KR102829078B1 (ko) 2020-06-30 2025-07-04 리유니온 뉴로사이언스 인코포레이티드 트립타민 전구약물
KR20230128451A (ko) * 2020-11-06 2023-09-05 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비노이드 캡슐화 기술
US11242328B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US11242330B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Organic catalyst and method for preparation of aromatic tricyclic pyrans
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB313977A (en) * 1927-12-21 1929-06-21 British United Shoe Machinery Improvements in or relating to boot or shoe sewing machines or methods of making boots or shoes by the use thereof
JPS5518709B2 (enExample) * 1970-02-13 1980-05-21
US4933363A (en) * 1988-08-16 1990-06-12 Elsohly Mahmoud A Method for effecting systemic delivery of delta-9-tetrahydrocannabinol
US6040298A (en) * 1992-12-23 2000-03-21 Oclassen Pharmaceuticals, Inc. Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US6008383A (en) * 1998-10-26 1999-12-28 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
US20060078955A1 (en) * 2004-10-13 2006-04-13 Lin-Zhi International Method for retrieving delta9-THC from oral fluid
BRPI0516922A (pt) * 2004-11-02 2008-09-23 New River Pharmaceuticals Inc composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
CN101516333A (zh) * 2006-08-04 2009-08-26 英西斯治疗学股份有限公司 水性屈大麻酚制剂
WO2008134668A2 (en) * 2007-04-27 2008-11-06 Alexza Pharmaceuticals, Inc. Heat-labile prodrugs
JP6073043B2 (ja) * 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
EP2211760A4 (en) * 2007-10-17 2013-09-18 Axxia Pharmaceuticals Llc POLYMER DRUG DELIVERY SYSTEMS AND METHODS OF EXTRUSION OF THERMOPLASTIC COMPOUNDS TO PRODUCE THESE SYSTEMS
WO2009073633A1 (en) * 2007-11-30 2009-06-11 Alltranz Inc. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
HUE032158T2 (en) * 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters

Also Published As

Publication number Publication date
EP2352497A4 (en) 2012-08-01
US20110275555A1 (en) 2011-11-10
HUE032158T2 (en) 2017-09-28
WO2010051541A2 (en) 2010-05-06
US9630941B2 (en) 2017-04-25
EP2352497A2 (en) 2011-08-10
JP2012507568A (ja) 2012-03-29
CA2741862A1 (en) 2010-05-06
HK1158517A1 (en) 2012-07-20
US8809261B2 (en) 2014-08-19
WO2010051541A3 (en) 2010-07-08
US20150045282A1 (en) 2015-02-12
DK2352497T3 (en) 2017-04-03
ES2622582T3 (es) 2017-07-06
EP2352497B1 (en) 2017-02-22
PL2352497T3 (pl) 2017-08-31
CA2741862C (en) 2017-10-17
AU2009308665B2 (en) 2015-10-22
AU2009308665A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
JP5739344B2 (ja) Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法
CN1052482A (zh) 氨基酸衍生物
CN101624376B (zh) 取代酰肼类化合物及其应用
CN103641925B (zh) 水溶性多聚糖与紫杉烷类化合物的共价聚化合物，其制备方法及医药用途
EP2064177B1 (en) Protease inhibitors
CN115385875B (zh) 一类紫杉醇衍生物及其制备方法和用途
US20050220753A1 (en) Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them
CN103992310A (zh) 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
JP2008532928A (ja) マクロライドとクマリンからなる抗炎症性複合体
CN113773259A (zh) 病毒主蛋白酶抑制剂及其制备方法和用途
CN105085455A (zh) 唾液酸类似物或其药学上可接受的盐及其应用
CN117384136A (zh) 一种no供体型抗真菌化合物及其制法和应用
HK1158517B (en) Process of preparation of delta-9-thc-amino acid esters
CN112851626B (zh) 一类左旋双环吗啉，其制备方法、药物组合物和应用
JP4413427B2 (ja) ヌクレオシド
CN109420179B (zh) 多烯紫杉烷靶向前药及其抗结肠癌药用用途
CN110922450B (zh) Psma激活式抗肿瘤前药cpt-x及其制备方法和应用
WO2017101785A1 (zh) 一种化合物、其制备方法、药物组合物及其用途
CN108101951A (zh) 一种甾体糖苷类化合物的制备方法及其在制备抗结核病药物中的应用
WO2023065667A1 (zh) 新型氘代苯并噻唑类化合物、其制备方法、组合物及应用
CN120040321B (zh) 基于疏水标签技术的神经氨酸酶抑制剂及其制备方法、衍生物、药物组合物和应用
CN115160234B (zh) 含芳基乙酸酯的1,4,5-三取代咪唑类化合物、制备方法及应用
CN112961081B (zh) 一种联苯甲酰胺脲类化合物及其制备方法和应用
CN1259314C (zh) 亲水性聚合物－黄酮结合物以及包含该结合物的药物组合物
HK40086425A (zh) 秋水仙碱衍生物的制备方法及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140418

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141105

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150423

R150 Certificate of patent or registration of utility model

Ref document number: 5739344

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250